Poseida’s Solid Tumor CAR-T Shows Early Promise, But Safety Will Be Closely Watched
Promising Signs In Prostate Cancer
Developing CAR-Ts against solid tumors that are both safe and effective is proving a huge technical challenge, but San Diego biotech Poseida believes it has made important progress.
You may also be interested in...
The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.
Takeda will use Poseida’s non-viral delivery and gene-editing capabilities for six liver- and hematopoietic stem cell-targeted gene therapies. The agreement follows recent gene therapy tie-ups with Selecta and Genevant.
Novartis is playing catch-up in PD-1 inhibitors but could soon claim a best-in-class competitor in first-line esophageal cancer.